DEA Reiterates Stance on Delta-8, Delta-9, and THCA in 2025 Letter

A 2025 letter from the Drug Enforcement Administration reaffirmed that synthetically derived cannabinoids — including most commercial delta-8 — remain Schedule I controlled substances, while declining to explicitly classify naturally occurring tetrahydrocannabinolic acid (THCA) in compliant hemp.

Arlington, Va. — August 14, 2025. The Drug Enforcement Administration sent a letter in response to congressional and industry inquiries reaffirming long-standing agency positions on hemp-derived cannabinoids. The letter, first reported by Marijuana Moment, restates positions DEA has articulated since 2020-2023 rather than introducing new policy.

The letter makes three points. First, DEA reiterates that synthetically derived tetrahydrocannabinols are Schedule I controlled substances under the Controlled Substances Act, regardless of source. The agency has applied this framing to the most common commercial route to delta-8: chemical conversion from CBD using acids and solvents.

Second, DEA distinguishes synthetic conversion from naturally occurring cannabinoids in hemp that meets the federal definition (delta-9 ≤0.3% by dry weight). Cannabinoids that are present in the plant and not chemically converted, the letter says, fall under the 2018 Farm Bill framework so long as the source plant qualifies as hemp.

Third, the letter does not explicitly address tetrahydrocannabinolic acid (THCA) by name. THCA is the non-decarboxylated acid form naturally present in raw cannabis flower; it is not delta-9 THC and is not synthetically derived. The letter’s framework — naturally occurring cannabinoids in compliant hemp are not controlled — would apply to THCA in raw flower that meets the delta-9 threshold, though DEA stops short of saying so directly.

Industry attorneys quoted by Hemp Industry Daily characterized the letter as “useful clarification, not a position change.” Critics — including some state attorneys general and licensed-cannabis trade groups — argue DEA should explicitly close what they call the THCA loophole through the rulemaking process.

DEA enforcement priorities, according to the letter, remain focused on synthetically converted cannabinoids, products marketed to minors, and trafficking of controlled-substance-equivalent material across state lines. The agency has not announced new enforcement actions specifically targeting compliant THCA flower.

What it means for consumers

DEA’s letter does not change anything for THCA flower that complies with the 2018 Farm Bill. It also does not provide an affirmative federal “safe harbor” — no DEA letter creates one. THCA in the form of raw, federally compliant hemp flower remains in the same uncertain federal-legal status it has occupied since 2018: not explicitly listed, not explicitly exempted.

Delta-8 and most commercial “hemp-derived delta-9 gummies” are a different story. Both rely on chemical conversion that DEA has consistently said falls under Schedule I. State laws vary — see our state legal map for where each cannabinoid stands locally.

Sources

• DEA — Drug Scheduling
• Marijuana Moment — DEA hemp coverage
• Hemp Industry Daily

Related

• Is THCA the Same as Delta-9 THC?
• What Is the THCA Loophole?
• Delta-8 vs THCA: Legal and Chemical Differences